

## Gambia Support for Pentavalent Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Gambia			
<b>2. Grant number:</b> 17-GMB-04c-X / /			
<b>3. Date of Decision Letter:</b> 16th of December 2016			
<b>4. Date of the Partnership Framework Agreement:</b> 3 February 2014			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>7</sup>:</b> 2009 -2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2009-2016	2017	Total <sup>8</sup>
Programme Budget (US\$)	US\$4,400,814 <sup>9</sup>	137,000	US\$4,537,814
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable.			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>10</sup>			
Type of supplies to be purchased with Gavi funds in each year	2009-2016		2017
Number of Pentavalent vaccines doses			114,000
Annual Amounts (US\$)	US\$4,400,814 <sup>11</sup>		137,000
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			
<b>14. Co-financing obligations:</b> Reference code: 17-GMB-04c-X-C According to the co-financing policy, the Country falls within the group Initial self-financing.			

<sup>7</sup> This is the entire duration of the Programme.

<sup>8</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>9</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>10</sup> This is the amount that Gavi has approved.

<sup>11</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.	
Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	23,000
Value of vaccine doses (US\$)	26,842
Total co-financing payments (US\$) (including freight)	27,500
<b>15. Operational support for campaigns:</b> Not applicable	
<b>16. Additional reporting requirements:</b> Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b>	
Not applicable	
<i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>	
<b>18. Other conditions:</b> Not applicable	

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

16th of December 2016